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ABSTRACT	50	 	51	 Genome-wide	 association	 studies	 (GWAS)	 have	 identified	 markers	 within	 the	52	
WNT4	 region	 on	 chromosome	 1p36.12	 showing	 consistent	 and	 strong	53	 association	 with	 increasing	 endometriosis	 risk.	 Fine	 mapping	 using	 sequence	54	 and	 imputed	genotype	data	has	revealed	strong	candidates	 for	 the	causal	SNPs	55	 within	these	critical	regions;	however,	the	molecular	pathogenesis	of	these	SNPs	56	 is	currently	unknown.	We	used	gene	expression	data	collected	from	whole	blood	57	 from	 862	 individuals	 and	 endometrial	 tissue	 from	 136	 individuals	 from	58	 independent	 populations	 of	 European	 descent	 to	 examine	 the	 mechanism	59	 underlying	endometriosis	susceptibility.	Association	mapping	results	from 7,090	60	 individuals	 (2,594	 cases	 and	 4,496	 controls)	 supported	 rs3820282	 as	 the	 SNP	61	 with	 strongest	 association	 for	 endometriosis	 risk	 (p=1.84×10-5,	 OR=1.244	62	 (1.126-1.375)).	SNP	rs3820282	is	a	significant	eQTL	in	whole	blood	decreasing	63	 expression	of	LINC00339	(also	known	as	HSPC157)	and	increasing	expression	of	64	
CDC42	(p=2.0	x10-54	and	4.5x10-4	respectively).	The	largest	effects	were	for	two	65	
LINC00339	probes	 (p=2.0	x10-54;	1.0	x10-34).	The	eQTL	 for	LINC00339	was	also	66	 observed	in	endometrial	tissue	(p=2.4	x10-8)	with	the	same	direction	of	effect	for	67	 both	 whole	 blood	 and	 endometrial	 tissue.	 There	 was	 no	 evidence	 for	 eQTL	68	 effects	 for	WNT4.	 Chromatin	 conformation	 capture	 provides	 evidence	 for	 risk	69	 SNPs	interacting	with	the	promoters	of	both	LINC00339	and	CDC4	and	luciferase	70	 reporter	assays	suggest	the	risk	SNP	rs12038474	is	 located	in	a	transcriptional	71	 silencer	 for	CDC42	 and	 the	 risk	allele	 increases	expression	of	CDC42.	However,	72	 no	effect	of	rs3820282	was	observed	in	LINC00339	expression	in	Ishikawa	cells.	73	 Taken	 together	 our	 results	 suggest	 that	 SNPs	 increasing	 endometriosis	 risk	 in	74	 this	region	act	through	CDC42,	but	further	functional	studies	are	required	to	rule	75	 out	inverse	regulation	of	both	LINC00339	and	CDC42.			76	 	77	 	78	 	79	 	80	 	81	 	82	
	83	
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INTRODUCTION	84	 	85	 Endometriosis	 is	 a	 common	 gynaecological	 disease,	 defined	 as	 the	 presence	 of	86	 endometrial	tissue	outside	of	the	uterus	in	lesions	containing	endometrial	glands	87	 and	 stroma1.	 It	 is	 associated	with	 severe	pelvic	pain	 and	 infertility	 affecting	6-88	 10%2	 of	 women	 during	 their	 reproductive	 years	 and	 20-50%	 of	 women	 with	89	 infertility3,4.	There	 is	 limited	knowledge	of	 the	aetiology	and	pathogenesis,	and	90	 accurate	 clinical	 diagnosis	 is	 usually	 by	 laparoscopy,	 an	 invasive	 and	 costly	91	 procedure.		92	 	93	 Susceptibility	to	endometriosis	is	known	to	be	influenced	by	genetic	factors,	with	94	 heritability	 of	 ~0.5	 from	 twin	 studies5.	 Meta-analysis	 of	 two	 genome-wide	95	 association	(GWA)	studies6,7	identified	a	genome-wide	significant	association	for	96	 single	nucleotide	polymorphism	(SNP)	rs7521902	on	1p36.12	close	to	WNT46,8,	97	 a	 critical	 and	 well-known	 regulator	 of	 uterine	 development.	 Further	 GWA	98	 studies	 have	 been	 published	 that	 replicate	 the	 original	 association	 within	 the	99	 1p36.12	region9,10.	100	 	101	 While	 GWA	 studies	 have	 proven	 to	 be	 powerful	 tools	 for	 identification	 of	 loci	102	 influencing	 disease	 susceptibility,	 the	 results	 have	 revealed	 little	 about	 the	103	 nature	 of	 the	 genetic	 component	 to	 these	 phenotypes.	 For	 endometriosis,	 fine	104	 mapping	 using	 sequence11	 and	 imputed	 genotype	 data8	 has	 identified	 the	105	 strongest	signals	within	the	WNT4	gene	in	the	1p36.12	region11,	however,	causal	106	 variants	and	molecular	pathogenesis	are	currently	unknown.	107	 	108	 One	common	mechanism	by	which	GWA	 loci	 influence	disease	 susceptibility	 is	109	 though	mediating	RNA	transcription12.	For	most	genes	there	are	extensive	inter-110	 individual	 differences	 in	 RNA	 levels13,	 and	 much	 of	 that	 variation	 is	 due	 to	111	 genetic	 factors14-16.	Loci	 responsible	 for	 this	 transcription	variation	are	 termed	112	 expression	 Quantitative	 Trait	 Loci	 (eQTL),	 and	 their	 sentinel	 SNPs	 are	 often	113	 defined	as	eSNPs.	Variation	in	genomic	DNA	can	affect	transcription	in	multiple	114	 ways.	Most	 intuitively	 perhaps,	 eSNPs	 represent	 allelic	 variation	 in	 regulatory	115	 elements	within	 the	cis-region	of	 transcripts	 that	 alter	 their	 expression	 level17.	116	 However,	 given	 high	 levels	 of	 localised	 linkage	 disequilibrium	 (LD),	 often	117	
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spanning	multiple	genes,	the	overlap	of	eQTLs	and	GWAS	loci	can	be	coincidental	118	 and	not	driven	by	the	same	functional	variants.		119	 	120	 In	addition	to	the	association	with	endometriosis,	variation	at	the	1p36	region	is	121	 also	associated	with	bone	mineral	density	(BMD)	and	a	risk	of	ovarian	cancer18.	122	 The	 primary	 BMD	 signal	 is	 located	 close	 to	 ZBTB40,	 and	 there	 is	 a	 secondary	123	 signal	that	overlaps	with	our	association	signal	near	WNT419.	The	primary	signal	124	 near	 ZBTB40	 is	 correlated	 with	 reduced	 expression	 of	 WNT4	 in	 fibroblasts,	125	 osteoblasts,	and	adipose	tissue19,20.	In	ovarian	cancer,	the	most strongly associated 126	
variant	at	the	1p36	locus	is	located	in	the	promoter	of	WNT421.	Data	from	ovarian	127	 tumour	 cell	 lines	 identified	 a	 cis-eQTL	 for	 CDC42	 for	 SNPs	 in	 the	 region20,22.		128	 Variants	associated	with	endometriosis	at	1p36	could	act	through	one	of	several	129	 genes,	and	this	may	be	tissue	specific.		130	 	131	 Here	 we	 present	 results	 from	 a	 study	 investigating	 gene	 expression	 data	132	 collected	 from	 whole	 blood	 and	 endometrial	 tissue	 from	 independent	133	 populations	to	identify	eQTLs	shared	between	blood	and	endometrial	tissue	for	134	 loci	 within	 1p36.12.	 We	 show	 that	 the	 mechanism	 underlying	 endometriosis	135	 susceptibility	does	not	act	through	regulation	of	the	strong	functional	candidate	136	
WNT4,	 but	 through	 nearby	 genes,	 LINC00339	 (ENSG00000218510),	 currently	137	 annotated	 as	 a	 long	 non-coding	 RNA	 and	 Cell	 Division	 Control	 Protein	 42	138	 (CDC42)	on	chromosome	one.	We	provide	evidence	of	shared	causal	loci	for	SNPs	139	 increasing	 endometriosis	 risk	 and	 eQTLs	 controlling	 expression	 levels	 of	140	
LINC00339	and	CDC42	in	blood	and	LINC00339	in	endometrial	tissue.		 	141	
	 5	
RESULTS	142	 	143	 There	 is	 substantial	 evidence	 for	 genetic	 association	 with	 endometriosis	144	 susceptibility	at	chromosome	1p36.12	for	a	block	of	SNPs	in	high	LD	(Fig.	1)	that	145	 spans	 ~130	 kb	 and	 includes	 the	 genes	WNT4	 and	 CDC42,	 and	 the	 non-coding	146	 RNA	LINC00339	 (also	 known	as	HSPC157).	 In	 this	 study,	we	 genotyped	 coding	147	 variants	 in	 all	 genes	 across	 the	 region	 in	 Australian	 cases	 and	 controls	 and	148	 combined	 the	 genotype	 data	 with	 previous	 GWAS	 results.	 We	 analysed	 227	149	 exome	variants	from	the	region	around	rs3820282	(+/-	2.25	Mb),	and	there	was	150	 no	evidence	for	association	with	any	coding	variants.	In	agreement	with	previous	151	 studies,	 the	 three	 SNPs	 showing	 the	 strongest	 association	 with	 endometriosis	152	 risk	were	rs3820282,	rs56318008,	and	rs55938609	(Table	1).	SNP	rs3820282	153	 [A/G]	 located	 at	 base-pair	 22468215	 in	 intron	 one	 of	WNT4	 (p=1.84	 x	 10-5,	154	 OR=1.24	(1.126-1.375))	is	in	strong	LD	(r2>0.95,	1000	Genome	CEU	population)	155	 with	 the	 next	 two	 most	 significant	 SNPs	 (rs56318008	 and	 rs55938609).	156	 Conditional	analysis	on	rs3820282	including	all	polymorphic	coding	variants	in	157	
WNT4,	CDC42,	LINC00339,	and	other	genes	in	the	region	showed	no	evidence	of	158	 additional	independent	signals.		159	 	160	
Effect	of	endometriosis	SNPs	at	1p36.12	on	RNA	transcription	in	whole	blood	161	 	162	 Within	the	1p36.12	locus,	there	are	nine	RefSeq	genes	that	include	one	or	more	163	 mRNA	transcript	probes	assayed	on	the	Illumina	HT12-v4.0	array	and	expressed	164	 in	 RNA	 samples	 from	 whole	 blood	 in	 the	 Brisbane	 Systems	 Genetics	 Study	165	 (BSGS)23.	 These	 gene	 are;	 C1QA,	 C1QB,	 C1QC,	 CDC42,	 EPHA8,	 LINC00339,	166	
LDLRAD2,	USP48	and	ZBTB40.	After	quality	control	(see	Methods)	there	remain	a	167	 total	 of	 14	 probes	 tagging	 transcripts	 of	 the	 nine	 genes	 within	 1p36.12.	168	 Phenotypic	 correlations	 between	 the	 normalised	 expression	 levels	 show	 a	 low	169	 level	 of	 co-expression	 of	 transcripts	 within	 the	 1p36.12	 locus	 (Supporting	170	
material	figure	1).	Probes	located	within	WNT4	were	not	detected	as	expressed	171	 in	 the	 BSGS	 sample,	 in	 line	 with	 previous	 studies	 that	 fail	 to	 identify	WNT4	172	 transcripts	expressed	in	blood24,25.	173	 	174	
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We	 initially	 investigated	 concurrence	 between	 the	 endometriosis	 fine-mapped	175	 sentinel	 SNP	 rs3820282	 and	 eQTLs	 for	 these	 14	 probes	 (Table	 2).	 The	176	 expression	 levels	 of	 three	 of	 the	 14	 probes	 in	 1p36.12	 show	 significant	177	 association	with	rs3820282	genotypes	after	correcting	for	multiple	testing.	The	178	 two	probes	with	the	largest	effect	(p=2.0	x10-54;	1.0	x10-34)	were	located	in	the	179	 long	non-coding	RNA	LINC00339	(lncRNA)	(Figure	1).	LINC00339	is	expressed	in	180	 a	wide	 range	 of	 healthy	 human	 tissues,	 including	 hematopoietic	 cells,	 ovaries,	181	 and	 uterus24,25.	 In	 blood,	 each	 copy	 of	 the	 risk	 allele	 (A)	 for	 endometriosis	182	 susceptibility	 of	 rs3820282	 decreased	 the	 expression	 levels	 of	 the	 LINC00339	183	 probes	 ILMN_3272768	 (ENST00000434233)	 by	 0.86	 standard	 deviations	 (SE	184	 0.07)	 and	 ILMN_3194087	 (ENST00000404210)	 by	 one	 standard	 deviation	 (SE	185	 0.06)	(Figure	2).	SNP	rs3820282	has	a	smaller,	but	still	significant	effect	on	the	186	 expression	levels	of	ILMN_1675156	(ENST00000344548)	in	CDC42	(P=4.4	x10-4)	187	 (Table	2,	Figures	1	and	2.	For	CDC42,	each	copy	of	the	endometriosis	risk	allele	188	 (A),	 expression	 levels	 increased	 by	 0.24	 standard	 deviations	 (SE	 0.07).	 The	189	 direction	 of	 the	 allelic	 effects	 of	 rs3820282	 on	 whole	 blood	 expression	 of	190	
LINC00339	and	CDC42	is	consistent	with	previously	reported	results26.			191	 	192	 For	 the	 three	 probes	 located	 in	 1p36.12	 with	 significant	 eQTL	 effects	 for	193	 rs3820282,	 we	 performed	 a	 conditional	 analysis	 and	 identified	 secondary,	194	 independent	eQTLs	 for	all	 three	probes	 (Supporting	material	 table	 1).	While	195	 the	 eSNPs	 were	 different,	 no	 tertiary	 eQTL	 were	 detected	 after	 additional	196	 conditional	analyses	fitting	each	of	the	secondary	eSNPs	(see	methods).		197	 	198	
Expression	of	transcripts	at	1p36.12	in	endometrial	tissue	199	
	200	 Capture	 sequence	 of	 transcripts	 within	 this	 region	demonstrate	WNT4,	 CDC42	201	 and	 LINC00339	 are	 all	 expressed	 in	 endometrium	 with	 multiple	 transcripts	202	 (Montgomery	 and	 Shakhbazov	 unpublished).	We	 analysed	 gene	 expression	 for	203	 probes	in	this	region	in	endometrial	samples	from	Illumina	HT-12v4	expression	204	 arrays	and	after	quality	control,	there	were	data	for	three	probes	for	LINC00339,	205	 two	 probes	 for	 CDC42	 and	 one	 probe	 for	WNT4.	 There	 was	 no	 evidence	 for	206	 effects	of	stage	of	the	menstrual	cycle	on	LINC00339	expression.	The	two	probes	207	
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for	CDC42	are	located	at	5’	(ILMN_1675156)	and	3’	end	(ILMN_1738424)	of	the	208	 gene.	 The	 CDC42	 probe	 at	 3’	 end	 (ILMN_1738424)	 and	 the	 WNT4	 probe	209	 (ILMN_1666392)	 showed	nominally	 significant	evidence	 (p=0.013	and	p=0.009	210	 respectively)	for	differences	across	the	menstrual	cycle,	where	both	CDC42	and	211	
WNT4	 expression	was	 highest	 in	 the	 early	 proliferative	 phase.	 The	 differences	212	 were	not	significant	after	correction	for	multiple	testing.	We	found	no	evidence	213	 for	 differences	 in	 expression	 levels	 between	 endometriosis	 cases	 and	 controls	214	 for	any	assays	after	adjusting	results	for	the	stage	of	the	cycle.	215	 	216	
The	 effect	 of	 endometriosis-associated	 SNPs	 on	 RNA	 transcription	 in	217	
endometrial	tissue	is	in	the	same	direction	as	in	blood.	218	 	219	 For	SNPs	in	the	region	typed	on	the	Sequenom	MassARRAY,	effects	of	genotype	220	 on	 gene	 expression	 were	 tested	 after	 fitting	 stage	 of	 the	 cycle	 as	 a	 covariate.	221	 Expression	 levels	 for	 LINC00339	 probes	 (ILMN_1901198,	 ILMN_3194087,	222	 ILMN_3272768)	 all	 showed	 significant	 eQTLs	 with	 rs3820282	 (p<7.4	 x10-8)	223	 (Table	3,	Figure	2),	with	a	comparable	estimated	effect	size	for	each	copy	of	the	224	 risk	allele	[A]	of	-0.55	in	endometrial	tissue.	There	were	no	significant	effects	of	225	 SNP	 genotypes	 on	 the	 expression	 of	 CDC42	 or	 WNT4	 in	 endometrial	 tissue.	226	 However,	 small	 differences	 in	 expression	 observed	 for	 CDC42	 probe	227	 ILMN_1675156	 showed	 the	 same	 direction	 of	 effect	 as	 in	 RNA	 samples	 from	228	 whole	 blood	 with	 increased	 expression	 associated	 with	 the	 risk	 alleles	 for	229	 rs3820282	(Figure	2).		230	 	231	 We	 also	 observed	 the	 secondary	 eQTL	 in	 endometrial	 tissue	 for	 LINC00339	232	 previously	 identified	 in	 whole	 blood	 RNA	with	 rs12061255	 (p=1.45	 x10-9;	 LD	233	 between	rs10917120	and	rs12061255	is	r2	=1).	The	result	remained	significant	234	 after	correcting	 for	multiple	 testing.	There	was	no	evidence	 for	 the	association	235	 between	 rs12061255	 and	 endometriosis	 risk	 (p=0.7068)	 and	 no	 significant	236	 effects	 of	 this	 SNP	 on	 CDC42	 and	 WNT4	 expression	 in	 endometrium.	237	 Interestingly,	 the	 risk	 allele	 (minor	 allele,	 A)	 for	 the	 key	 endometriosis	 SNP	238	 rs3820282	was	associated	with	a	decrease	 in	LINC00339	 expression,	while	 the	239	
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minor	 allele	 (T)	 of	 SNP	 rs12061255	 showed	 an	 increase	 in	 LINC00339	240	 expression.		241	 	242	 While	LINC00339	is	designated	as	a	long	non-coding	RNA,	its	status	is	unclear	as	243	 the	 sequence	 has	 a	 small	 open	 reading	 frame	with	 a	 strongly	 predicted	 signal	244	 peptide	and	N-terminal	trans-membrane	domain.	However,	mapping	of	peptides,	245	 identified	by	mass	spectrometry,	 in	GM12878	and	K562	cell	 lines27	and	kidney,	246	 urine	and	plasma28	samples	reveal	no	known	translated	proteins	located	within	247	
LINC00339	coordinates.	Sequence	data	identifies	a	four	bp	deletion	in	the	second	248	 exon	 of	 the	 LINC00339	 transcript	 (rs3036899)	 and	 capture	 sequence	 data	 for	249	
LINC00339	 transcripts	 expressed	 in	 human	 endometrium	 (Montgomery	 and	250	 Shakhbazov	 unpublished)	 show	 all	 three	 alleles	 for	 this	 insertion/deletion	251	 variant	 located	 within	 the	mRNA	 sequence.	 If	 translated,	 this	 deletion	 variant	252	 would	 result	 in	 a	 truncated	protein	without	 the	 trans-membrane	domain.		Our	253	 results	show	this	four	base-pair	deletion	in	the	second	exon	of	LINC00339	gene	is	254	 in	low	LD	with	the	sentinel	SNP	associated	with	endometriosis	risk	(rs3820282,	255	
r2	=0.05).	However,	there	is	LD	(r2	=0.36)	with	the	alternative	SNP	rs12061255	256	 that	shows	a	strong	eQTL	for	LINC00339,	but	no	association	with	endometriosis	257	 risk.		258	 	259	
Evidence	that	the	causal	variants	for	expression	and	endometriosis	risk	are	260	
the	same	261	 	262	 One	of	the	challenges	arising	from	both	GWAS	and	eQTL	analyses	is	the	precise	263	 identification	of	the	disease-causing	variant29.	There	was	strong	overlap	between	264	 the	local	pattern	of	SNP	effects	on	meta-analysis	p-values	for	endometriosis	risk	265	 and	 the	 blood	 expression	 p-values	 for	 the	 three	 transcripts	 (Figure	 1	 and	266	
supporting	material	figure	2).	However,	given	the	high	levels	of	LD	within	this	267	 region,	we	used	the	Regulatory	Trait	Concordance	(RTC)	method	of	Nica	et	al.30	268	 to	distinguish	between	shared	 loci	and	coincidental	overlaps	within	the	region.	269	 The	 RTC	 score	 ranges	 from	 0	 to	 1,	 with	 values	 closer	 to	 1	 indicating	 shared	270	 causal	 regulatory	 effects.	 All	 three	 probes	 had	 high	 RTC	 scores	 with	 the	271	 rs3820282	eSNP	(>=0.9)	 indicating	strong	evidence	of	shared	 loci	between	 the	272	
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endometriosis	 GWAS	 loci	 and	 eQTLs	 for	 LINC00339	 and	 CDC42	 (supporting	273	
material	table	2).	The	RTC	scores	of	the	secondary	eQTLs	were	<	0.1	providing	274	 further	 evidence	 that	 only	 the	 rs3820282	 eQTL	 is	 likely	 to	 have	 a	 role	 in	275	 endometriosis	susceptibility.	Because	of	 the	 limited	number	of	genotyped	SNPs	276	 in	 the	endometrial	 sample	we	were	unable	 to	perform	the	RTC	analysis	 to	 test	277	 for	the	congruence	of	endometriosis	causal	loci	and	endometrial	eQTL.	278	 	279	 In	 addition	 to	 RTC	we	 used	 a	 Summary-data-based	Mendelian	 Randomization	280	 (SMR)	 method31	 to	 test	 further	 for	 the	 functionally	 relevant	 element(s)	281	 underlying	 the	 endometriosis	 GWAS	 loci	 at	 1p36.12.	 SMR	 adopts	 a	Mendelian	282	 Randomisation	 approach	 to	 test	 the	 functional	 association	 between	 the	283	 expression	level	of	a	gene	(measured	by	probes)	and	a	trait.	We	employed	SMR	284	 to	examine	the	association	between	eQTL	data23	for	each	of	the	14	probes	within	285	 the	1p36.12	region	and	endometriosis	GWAS	data8.	At	a	Bonferroni	adjusted	p-286	 value	threshold	(0.05/14)	SMR	identified	significant	associations	between	eQTLs	287	 for	 LINC00339	 and	 CDC42	 and	 the	 endometriosis	 GWAS	 loci	 at	 1p36.12	288	 (Supporting	 material	 table	 2).	 Furthermore,	 we	 found	 no	 significant	 (p=1.5	289	 x10-1)	 association	 for	 a	 conditional	 analysis	 between	 the	 secondary	 eQTL	 for	290	
LINC00339	 (rs10917120)	 and	 endometriosis.	However,	 it	 is	 important	 to	note,	291	 that	 both	 RTC	 and	 SMR	 do	 not	 distinguish	 between	 causal	 relationships	 and	292	 pleiotropy.		293	 	294	
The	 top	 risk	 SNPs	 fall	 within	 putative	 regulatory	 elements	 (PREs)	 that	295	
frequently	interact	with	the	LINC00339	and	CDC42	promoter	regions	296	 	297	 Chromosome	 conformation	 capture	 (3C)	 was	 used	 to	 investigate	 chromatin	298	 interactions	between	 the	 candidate	 target	 genes	 and	 risk-associated	SNPs.	The	299	
LINC00339	 promoter	 showed	 a	 strong	 interaction	 with	 a	 putative	 regulatory	300	 element	(PRE1)	 located	~115	kb	centromeric	to	the	gene	 in	Ishikawa	cell	 lines	301	 (Figure	 3	 and	 Supporting	 material	 figure	 3).	 The	 region	 spans	 the	WNT4	302	 promoter	 and	 includes	 the	 top	 risk	 SNP	 rs3820282.	 An	 interaction	 was	 also	303	 detected	between	the	CDC42	promoter	and	another	PRE	(called	PRE2)	located	in	304	 the	first	 intron	of	CDC42	 (~24	kb	centromeric	to	the	promoter).	PRE2	contains	305	
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SNP	rs12038474,	which	showed	a	strong	signal	for	endometriosis	risk	(p=1.73	x	306	 10-4,	 OR=1.21	 (1.096-1.341))	 and	 is	 in	 LD	 (r2>0.77,	 1000	 Genome	 CEU	307	 population)	with	the	top	risk	SNP	rs3820282.	This	SNP	also	showed	a	significant	308	 eQTL	 for	 CDC42	 in	 BSGS	 whole	 blood	 samples	 (p=6.28	 x10-10).	 There	 was	 no	309	 evidence	 of	 interaction	 for	 any	 region	 or	 risk-associated	 SNP	 with	 WNT4.	310	 However,	 four	 SNPs	 close	 to	 the	WNT4	 promoter	 could	 not	 be	 resolved	 by	 3C	311	 (Figure	3	and	Supporting	material	figure	3).	312	 	313	 The	 regulatory	 capability	 of	 PRE1	 and	 PRE2,	 combined	 with	 the	 effects	 of	314	 candidate	 SNPs,	was	 further	 examined	 in	 luciferase	 reporter	 assays.	 For	PRE1,	315	 inclusion	 of	 the	 reference	 or	 risk	 allele	 of	 SNP	 rs3820282	 had	 no	 significant	316	 effect	on	the	LINC00339	promoter	activity	in	Ishikawa	cells	(Figure	3C).	On	the	317	 evidence	 from	 Ishikawa	 cells	 rs3820282	 is	 unlikely	 to	 act	 through	318	 transactivation	 of	 LINC00339.	 However,	 it	 is	 possible	 that	 rs3820282	 affects	319	 chromatin	 looping	 between	 the	 PRE	 and	 LINC00339:	 which	 would	 not	 be	320	 observed	in	a	luciferase	reporter	assay.	In	contrast,	PRE2	constructs	containing	321	 the	 reference	 allele	 of	 SNP	 rs12038474	 reduced	 CDC42	 promoter	 activity,	322	 suggesting	that	PRE2	can	act	as	a	transcriptional	silencer	(Figure	3C).	Consistent	323	 with	the	eQTL	analysis,	inclusion	of	the	minor	(risk-increasing)	allele	of	the	SNP	324	 significantly	increased	the	CDC42	promoter	activity	in	Ishikawa	cells.	Given	that	325	 SNP	rs3820282	may	alter	an	ESR1	binding	site,	we	also	examined	the	effects	of	326	 estrogen	 induction	 on	 PRE1,	 but	 observed	 no	 additional	 effects	 (Supporting	327	
material	figure	4).		 	328	
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DISCUSSION	329	 	330	 Studies	 in	 endometriosis	 report	 strong	 evidence	 for	 genetic	 association	 with	331	 disease	 risk	at	 chromosome	1p36.126,7	 in	an	LD	block	 that	 spans	genes	WNT4,	332	
CDC42,	 and	LINC00339	 (also	 known	 as	HSPC157).	 Conditional	 analyses	 for	 the	333	 strongest	signal	did	not	detect	any	evidence	for	additional	signals	in	the	region.	334	 Analysis	of	gene	expression	in	whole	blood18,24	identified	eQTLs	for	transcripts	in	335	 this	 region	 with	 the	 strongest	 evidence	 for	 LINC00339	 and	 also	 evidence	 for	336	 eQTLs	 for	 CDC4216,23.	 WNT4	 is	 not	 expressed	 in	 samples	 from	 whole	 blood.	337	 Endometriosis	 risk	 alleles	 decreased	 expression	 of	 LINC00339	 and	 increased	338	 expression	of	CDC42.	Results	from	a	large	meta-analysis	of	eQTL	data	from	blood	339	 show	a	strong	eQTL	for	CDC42	(p=9.8	x10-198)	located	directly	over	our	signal	for	340	 endometriosis	risk	(expression	data	for	LINC00339	probes	were	excluded	during	341	 quality	control	of	the	data	in	this	study)26.	The	signals	for	disease	association	and	342	 eQTLs	completely	overlap	and	regulatory	trait	concordance	and	summary-data-343	 base	 Mendelian	 Randomisation	 methods	 provide	 strong	 evidence	 for	 shared	344	 causal	regulatory	effects.	345	 	346	 The	 tissue(s)	 or	 cell	 types	 likely	 contributing	 to	 functional	 effects	 of	347	 endometriosis	 risk	 variants	 include	 viable	 endometrial	 tissue	 or	 endometrial	348	 stem	 cells	 deposited	 in	 the	 peritoneal	 cavity	 via	 retrograde	 menstruation32-34.	349	 We,	therefore,	analysed	expression	of	LINC00339,	CDC42	and	WNT4	 transcripts	350	 in	 RNA	 samples	 from	 endometrial	 tissue.	 Gene	 expression	 array	 results	 show	351	 that	 all	 three	 genes	 were	 expressed	 in	 the	 endometrium	 with	 evidence	 for	352	 differential	expression	of	CDC42	and	WNT4	during	the	menstrual	cycle.	WNT4	is	353	 known	to	be	critical	for	the	development	of	the	female	reproductive	tract35	and	354	 the	 level	 of	 WNT4	 mRNA	 expression	 was	 significantly	 lower	 in	 human	355	 endometrial	 carcinomas	 than	 in	 the	normal	endometrium36.	After	adjusting	 for	356	 the	stage	of	the	cycle,	we	did	not	observe	any	significant	effects	of	endometriosis	357	 risk	alleles	on	WNT4	expression	in	the	endometrium.	358	 	359	 There	was	 strong	 evidence	 for	 eQTLs	 for	 LINC00339	 in	 endometrium	 for	 SNP	360	 rs3820282	with	 the	 same	 direction	 of	 effect	 as	 the	 eQTLs	 in	 blood.	 Effects	 of	361	
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rs3820282	 on	CDC42	 expression	 in	 the	 endometrium	were	 not	 significant,	 but	362	 the	 direction	 of	 effect	 was	 similar	 to	 that	 observed	 in	 whole	 blood,	 where	363	 endometriosis	risk	alleles	increased	expression	of	CDC42.	LINC00339	and	CDC42	364	 represent	a	complex	locus	with	some	evidence	for	combined	LINC00339/CDC42	365	 transcripts	in	AceView37.	The	genes	encode	22	different	mRNAs,	18	alternatively	366	 spliced	variants,	and	four	unspliced	forms	with	putative	evidence	for	15	spliced	367	 mRNAs	encoding	proteins.	Results	suggest	variants	affecting	endometriosis	risk	368	 at	1p36	affect	 expression	of	 LINC00339	and	CDC42	 in	opposite	directions,	 but	369	 additional	studies	will	be	required	to	confirm	a	role	for	one	or	both	genes	in	the	370	 pathogenesis	of	endometriosis	or	ovarian	cancer.		371	 	372	 Little	 is	 known	 about	LINC00339	 function,	 despite	 near	 ubiquitous	 expression.	373	 Transcription	 at	 this	 locus	 is	 reported	 in	 pigs	 and	 cattle38,39.	 LINC00339	374	 expression	 appears	 to	 be	 inversely	 correlated	 with	 blood	 cholesterol	 levels;	375	 down-regulated	in	cells	from	patients	with	familial	hypercholesterolemia40,	and	376	 up-regulated	in	patients	with	low	baseline	LDL	levels41.	Given	that	the	risk	allele	377	 reduced	expression	of	LINC00339,	these	findings	are	consistent	with	significantly	378	 increased	LDL	 levels	 in	women	with	endometriosis42	but	do	 little	 to	 illuminate	379	 potential	 mechanisms	 of	 action.	 LINC00339	 was	 one	 of	 108	 cDNA	 clones	380	 identified	 by	 subtractive	 hybridization	 and	 up-regulated	 in	 endometriosis	381	 lesions	compared	with	normal	endometrium43.	However,	no	subsequent	studies	382	 have	 considered	LINC00339	 expression	 in	 endometriosis	 or	 identified	 possible	383	 casual	roles	in	endometriosis	risk.	In	our	results,	the	endometriosis	risk	allele	for	384	 rs3820282	 was	 associated	 with	 decreased	 expression	 of	 LINC00339	 in	 RNA	385	 samples	 from	 the	 endometrium	 and	 whole	 blood.	 We	 did	 not	 observe	 any	386	 differential	 expression	 of	 LINC00339	 across	 the	 menstrual	 cycle,	 but	 the	387	 endometriosis	 risk	 allele	 (A)	 for	 the	 sentinel	 SNP	 rs3820282	 may	 alter	 an	388	 estrogen	 receptor	 (ESR1)	 binding	 site	 in	 several	 cell	 types11	 and	LINC00339	 is	389	 over-expressed	 when	 the	 estrogen	 receptor	 is	 knocked	 down	 in	 MCF7	 breast	390	 cancer	cell	lines44.	391	 	392	 Endometriosis	is	considered	a	benign	disorder,	but	cells	in	endometrial	implants	393	 have	 increased	 capacity	 to	 proliferate,	 implant	 and	 grow	 in	 the	 peritoneal	394	
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cavity45.	 	CDC42,	 a	member	of	 the	Rho	 family	 of	GTPases,	 is	 known	 to	 act	 as	 a	395	 molecular	 switch	 that	 can	 activate	 some	 downstream	 targets46.	 It	 has	 been	396	 implicated	 in	 a	 variety	 of	 signalling	 cascades	 initiating	 changes	 in	 cellular	397	 processes	 including	 cell	 polarity,	 cytoskeleton	 remodelling,	 proliferation,	398	 migration,	 adhesion,	 membrane	 trafficking	 and	 transcription47,48.	 Increasing	399	 evidence	 has	 indicated	 that	 CDC42	 is	 involved	 in	 cell	 migration	 and	 tumour	400	 progression	 in	 multiple	 cancer	 types	 including	 hepatocellular	 carcinoma	 cells	401	 and	 colorectal	 cancer49-51.	 CDC42	 has	 been	 implicated	 in	 progression	 of	 both	402	 ovarian	and	breast	cancer52,53,				403	 	404	 Expression	 of	CDC42	 is	 reported54	 to	 be	 higher	 in	 ovarian	 endometriotic	 cysts	405	 compared	 to	 patients	 with	 adenomyosis	 suggesting	 increased	 expression	 of	406	
CDC42	 may	 contribute	 to	 the	 development	 of	 ovarian	 endometriosis.	 The	 key	407	 SNPs	 associated	 with	 endometriosis	 at	 the	 1p36	 locus	 are	 also	 strongly	408	 associated	 with	 risk	 for	 ovarian	 cancer21	 and	 endometriosis	 is	 a	 known	 risk	409	 factor	for	ovarian	cancer55	with	the	strongest	evidence	for	genetic	overlap	with	410	 clear	cell	ovarian	cancer56.		Gene	expression	studies	in	high-grade	serous	ovarian	411	 cancer	 (HGSOC)	 samples	 from	 The	 Cancer	 Genome	 Atlas	 (TCGA)	 project	412	 demonstrated	 that	 risk	 SNPs	 for	HGSOC	 at	 chromosome	 1p36	were	 eSNPs	 for	413	 CDC4222.	 Elevated	 expression	 of	 CDC42	 was	 associated	 with	 increased	 risk	 of	414	 HGSOC,	and	overexpression	of	the	gene	was	associated	with	shorter	population-415	 doubling	 times	 and	 reduced	 migration	 of	 cells	 in	 culture.	 The	 functional	 data	416	 from	 3C	 and	 luciferase	 reporter	 assays	 provide	 strong	 evidence	 that	 the	 SNP	417	 rs12038474,	associated	with	endometriosis	risk,	influences	promoter	activity	of	418	
CDC42.	 Taken	 together,	 results	 suggest	 CDC42	 plays	 an	 important	 role	 in	 the	419	 development	of	endometriosis	and	endometriomas,	and	progression	to	ovarian	420	 cancer	in	some	patients.	421	 	422	 We	identified	a	secondary	eQTL	for	LINC00339	in	the	region	in	both	whole	blood	423	 and	endometrial	RNA	samples.	The	second	eSNP	(rs12061255)	is	not	associated	424	 with	endometriosis	risk,	is	in	low	LD	with	endometriosis-associated	SNPs,	and	is	425	 not	associated	with	up-regulation	of	CDC42	expression.	This	is	further	supported	426	 by	the	larger	study	of	expression	in	blood	of	Westra	et	al.26,	where	there	was	no	427	
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evidence	 for	 eQTL	 effects	 of	 rs12061255	 on	 CDC42	 expression26.	 The	 second	428	 eQTL	 for	 LINC00339	 argues	 against	 a	 causal	 role	 for	 LINC00339	 acting	 alone.	429	 However,	 co-ordinated	 and	 inverse	 regulation	 of	 both	 LINC00339	 and	 CDC42	430	 expression	by	the	causal	variant(s)	associated	with	endometriosis	in	this	region	431	 may	be	important	for	SNP	effects	on	endometriosis	risk.			432	 	433	 The	association	 signals	 and	critical	 SNPs	 for	 risk	of	 endometriosis	 and	ovarian	434	 cancer	 at	 this	 region	 completely	 overlap8,21	 and	 SNPs	 with	 the	 strongest	435	 association	are	located	in	the	promoter	region	of	WNT4.	We	saw	no	evidence	for	436	 eQTL	 effects	 of	 rs3820282	 on	 WNT4	 expression	 in	 endometrium	 and	437	 transfection	 of	 wild-type	 and	 risk	 haplotype	WNT4	 promoter	 constructs	 into	438	 ovarian	 surface	 epithelial	 cells	 also	 had	 no	 significant	 effects	 on	 WNT4	439	 expression	 in	 luciferase	 reporter	 assays21.	 Candidate	 causal	 SNPs21	 with	 a	440	 likelihood	 of	 less	 that	 1:100	 for	 being	 causal	 in	 ovarian	 cancer	 span	 a	 region	441	 upstream	of	CDC42	and	across	WNT4	(chr1:	22,366,102-22,492,887).	Some	SNPs	442	 across	 the	 region	 are	 located	 in	 promoters	 and	putative	 enhancers	 in	 relevant	443	 tissues57	 and	 alter	 transcription	 factor	 binding	 sites	 including	444	 HMGA1/FOXJ3/SOX13	(rs10917130),	SMAD3	(rs3754496),	BRCA1	(rs2268179),	445	 and	ESR1	(rs3820282)11,57.			446	 	447	 In	 summary,	 this	 study	 of	 gene	 expression	 in	 whole	 blood	 and	 endometrium	448	 identified	LINC00339	 as	 the	 gene	with	 the	 strongest	 eQTL	with	 risk	 alleles	 for	449	 SNPs	 associated	 with	 endometriosis	 at	 chromosome	 1p36.12.	 There	 was	450	 evidence	 for	smaller,	but	opposite	effects	on	CDC42	 expression.	The	signals	 for	451	 disease	 association	 and	 eQTLs	 completely	 overlap	 and	 regulatory	 trait	452	 concordance	 and	 summary-data-base	 Mendelian	 Randomisation	 methods	453	 provide	strong	evidence	for	shared	loci,	although	they	are	unable	to	distinguish	454	 between	 causal	 relationships	 and	 pleiotropy.	 Results	 from	 chromatin	455	 conformation	 capture	 show	 strong	 interactions	 between	 putative	 regulatory	456	 elements	 containing	 endometriosis	 associated	 SNPs	 and	 the	 promoters	 of	457	
LINC00339	and	CDC42.	The	Luciferase	reporter	assays	support	a	direct	effect	of	458	 rs12038474	 on	 expression	 of	 CDC42,	 but	 we	 do	 not	 observe	 direct	 effects	 of	459	 rs3820282	on	LINC00339	expression	were	in	Ishikawa	cells.	Taken	together,	the	460	
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results	strongly	implicate	variation	in	expression	of	CDC42	in	endometriosis	risk.	461	 Additional	expression	and	functional	studies	will	be	necessary	evaluate	whether	462	 there	is	any	role	for	inverse	regulation	of	LINC00339	and	CDC42	to	determine	the	463	 role(s)	of	CDC42	in	regulating	risk	of	endometriosis	and	ovarian	cancer.	 	464	
	 16	
METHODS	465	 	466	
Genotyping	and	association	analyses		467	
	468	 A	 total	 of	 2,213	 surgically	 confirmed	 endometriosis	 cases	 and	 2,044	 controls	469	 were	genotyped	on	HumanCoreExome	chips	(Illumina	Inc,	San	Diego)6,58.	Cases	470	 and	 controls	 for	 the	 HumanCoreExome	 genotyping	 included	 all	 Australian	471	 samples	typed	on	Illumina	670-Quad	(cases)	and	610-Quad	(controls)	BeadChips	472	 (Illumina	Inc)6	for	our	previous	genome-wide	association	study	if	DNA	samples	473	 were	still	available.	Genotype	data	across	the	chromosome	1	region	for	the	same	474	 individuals	were	merged	 for	 Illumina	 I670/I610	 data,	 HumanCoreExome	 data,	475	 and	 Sequenom	 MassARRAY	 custom	 genotypes59	 from	 a	 subset	 of	 samples	476	 including	 930	 of	 the	 surgically	 confirmed	 cases	 with	 a	 family	 history	 of	477	 endometriosis	 and	 a	 control	 group	 of	 958	 unrelated	 women	 (recruited	 for	 a	478	 study	 of	 twins	 who	 self-reported	 that	 they	 had	 never	 been	 diagnosed	 with	479	 endometriosis)11.	 Standard	 quality	 control	 procedures	 were	 applied	 to	480	 individual	datasets	as	outlined	previously11.	Briefly,	SNPs	with	>5%	missing	rate,	481	 out	of	Hardy-Weinberg	Equilibrium	(p	 <	10-6)	 in	 controls	and	MAF	<	1%	were	482	 excluded.	 	 Samples	with	non-European	ancestry	or	with	 low	 call	 rates	 (<95%)	483	 were	excluded	from	the	downstream	analyses.		484	 	485	 The	 final	 combined	 Australian	 dataset	 consisted	 of	 2,594	 cases	 and	 4,496	486	 controls.	 Of	 the	 total	 7,090	 individuals	 in	 the	 combined	 dataset,	 6,503	 are	487	 unrelated	while	587	are	related	to	some	degree.	The	merged	data	was	imputed	488	 using	 the	MACH	 program60,61	 to	 impute	missing	 genotypes.	 The	 quality	 of	 the	489	 imputed	 genotypes	 was	 assessed	 by	 R2	 metric,	 which	 estimates	 the	 squared	490	 correlation	 between	 true	 and	 imputed	 genotypes.	 All	 SNPs	 passed	 standard	491	 imputation	quality	control	threshold	(R2	>0.3).	Association	analysis	for	markers	492	 across	 the	 1p36.12	 region	 was	 performed	 using	 an	 association	 analysis	 of	493	 imputed	 genotype	 dosage	 scores	 with	 endometriosis	 implemented	 through	494	 PLINK	software	(http://pngu.mgh.harvard.edu/purcell/plink/)62.	To	account	for	495	 relatedness	 in	 the	dataset,	 the	 analysis	was	 conducted	using	 a	 robust	 variance	496	 estimation	approach63,64	available	in	PLINK.		497	 	498	
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	499	
	500	
Gene	expression	in	whole	blood	501	 	502	 We	used	gene	expression	data	from	the	Brisbane	Systems	Genetics	Study	(BSGS)	503	 to	 investigate	 the	 effect	 of	 SNPs	 located	within	 1p36.12	 on	 cis-located	 probes.	504	 BSGS	 comprises	 862	 individuals	 of	 European	 descent	 from	 274	 independent	505	 families23.	 DNA	 samples	 from	 each	 individual	were	 genotyped	 on	 the	 Illumina	506	 610-Quad	 Beadchip	 by	 the	 Scientific	 Services	 Division	 at	 deCODE	 Genetics	507	 Iceland.	Full	details	of	genotyping	procedures	are	given	elsewhere23,65.	Filtered	508	 genotypes	 were	 then	 imputed	 to	 1000	 Genomes	 reference	 panel	 (release	 3.0)	509	 using	hapi-ur66	and	impute267.	SNPs	with	a	poor	imputation	quality	score	(R2	<	510	 0.3)	and	with	an	MAF	<	0.05	were	removed.		511	 	512	 Whole	blood	for	expression	profiling	was	collected	directly	 into	PAXgene	tubes	513	 (QIAGEN,	Valencia,	CA).	Total	RNA	was	extracted	from	PAXgene	tubes	using	the	514	 WB	gene	RNA	purification	kit	(QIAGEN,	Valencia,	CA).	RNA	from	all	samples	was	515	 run	 on	 an	 Agilent	 Bioanalyzer	 to	 assess	 RNA	 integrities	 and	 to	 estimate	 RNA	516	 concentrations.	RNA	was	amplified	and	converted	to	biotinylated	cRNA	using	the	517	 Ambion	Illumina	TotalPrep	RNA	Amplification	Kit	(Ambion).	518	 	519	 Expression	profiles	were	generated	by	hybridising	750	ng	of	 cRNA	 to	 Illumina	520	 HumanHT-12	 v4.0	 Beadchips	 according	 to	 Illumina	 whole-genome	 gene	521	 expression	 direct	 hybridization	 assay	 Guide	 (Illumina	 Inc,	 San	 Diego,	 USA).	522	 Briefly,	500	ng	of	total	RNA	were	used	to	generate	biotinylated	cRNA,	which	was	523	 fragmented	 and	 hybridised	 to	 an	 Illumina	 whole	 genome	 expression	 chip,	524	 HumanHT-12	 v4.0	 for	 18	 h	 at	 58oC.	 Beadchips	were	 then	washed	 and	 stained	525	 and	 subsequently	 scanned	 to	 obtain	 fluorescence	 intensities.	 Samples	 were	526	 scanned	using	an	Illumina	Bead	Array	Reader.	Samples	were	randomised	across	527	 chips	 and	 chip	 positions,	 with	 a	 check	 for	 balance	 across	 families,	 sex	 and	528	 generation.	529	 	530	
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The	following	normalisation	procedures	were	applied	to	the	raw	expression	data	531	 for	 the	 eQTL	 analysis.	 Pre-processing	 of	 data	 generated	 by	 the	 Illumina	 Bead	532	 Array	 Reader	was	 done	 using	 Illumina	 software,	 GenomeStudio	 (Illumina	 Inc.,	533	 San	 Diego).	 Pre-processing	 included;	 correction	 for	 chip	 background	 effects,	534	 removal	of	outlier	beads,	computation	of	average	bead	signal	and	calculation	of	535	 detection	p-values	using	negative	controls	present	on	the	array.	Removal	of	chip	536	 background	 effects	 can	 lead	 to	 negative	 expression	 levels	 for	 transcripts	 with	537	 low	 levels	 of	 expression.	 To	 avoid	 problems	 with	 further	 normalisation	538	 procedures,	 negative	 values	were	 denoted	 as	missing	 data	 identifiers.	 Thus,	 in	539	 subsequent	normalisation	procedures	and	analyses	samples	with	probes	coded	540	 as	 missing	 were	 ignored.	 Finally,	 we	 checked	 that	 probes	 did	 not	 contain	541	 sequence	variants	with	MAF	>0.05	in	both	the	1000Genomes	and	BSGS	cohorts.			542	 	543	
Quality	Control		544	 	545	 The	 Illumina	 HT-12	 v4.0	 chip	 contains	 22	 probes	 that	 tag	 transcripts	 located	546	 within	 the	 1p36.12	 region.	 To	 avoid	 spurious	 associations,	we	 removed	 seven	547	 probes,	mapping	 to	 five	RefSeq	 genes	 that	were	 not	 expressed	 in	 greater	 than	548	 10%	 of	 samples.	 These	 genes	 were	 also	 not	 expressed	 in	 GTEx	 whole	 blood	549	 data68.	Of	the	14	probes	remaining,	the	mean	of	the	proportion	of	samples	with	550	
p-values	 <0.05	was	 97%,	 implying	 that	 relatively	 little	missing	 data	 remained	551	 within	the	expression	dataset.		552	 	553	
Whole	blood	eQTL	554	 	555	 The	 gene	 expression	normalisation	 and	 eQTL	mapping	have	been	described	 in	556	 detail	 elsewhere16,23.	 However,	 we	 will	 briefly	 describe	 the	 methods	 here.	 To	557	 minimise	 the	 influence	of	overall	 signal	 levels,	which	may	reflect	RNA	quantity	558	 and	quality	rather	than	a	biological	difference	between	individuals,	the	following	559	 standardisation	 procedures	 were	 applied.	 Adjusted	 expression	 levels	 for	 each	560	 probe	 were	 transformed	 using	 a	 Quantile	 transformation69,70	 to	 achieve	 a	561	 stabilized	 distribution	 across	 average	 expression	 levels.	 Further	 normalisation	562	
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was	 performed	 to	 allow	 expression	 levels	 to	 be	 compared	 across	 chips	 and	563	 genes.	This	was	achieved	by	fitting	the	following	linear	mixed	model;	564	 	565	 ! = !"+ !"+ !	 (1)	566	 	567	 Where	!	is	a	vector	of	log-transformed	probe	expression	levels,	!	is	an	unknown	568	 vector	of	fixed	effects	of	the	batch	and	blood	cell	counts	(extraction	date,	gender,	569	 Red	 blood	 cells,	 platelets,	 neutrophils,	 monocytes,	 eosinophils,	 basophils,	 CD4,	570	 CD8,	CD19,	CD56).		!	is	an	unknown	vector	of	random	effects	of	batch	(chip	and	571	 chip	 position,	 age)	 with	 known	 design	 matrix	 Z,	 and	!	is	 a	 vector	 of	 residual	572	 errors.		The	residuals	from	this	model	were	standardised	to	z-scores	and	used	in	573	 all	further	analyses.	574	 	575	 The	 relationship	 between	 SNP	 genotypes	 and	 normalised	 probe	 expression	576	 levels	 had	 been	 tested	 for	 using	 a	 linear	 mixed	 model	 (--assoc	 command)	577	 implemented	 in	MERLIN71.	 	 SNP	 genotype	 effects	were	 estimated	 assuming	 an	578	 additive	genetic	model.	A	conditional	analysis	was	used	to	address	the	potential	579	 of	missing	secondary	eQTL	in	linkage	disequilibrium	(LD)	with	other	eQTL.	For	580	 each	 probe	 with	 an	 identified	 eQTL,	 we	 corrected	 for	 the	 main	 effects	 of	 the	581	 sentinel	eSNP	(SNP	with	the	 largest	R2)	by	regressing	 its	genotypes	against	 the	582	 expression	 levels.	 Residuals	 from	 this	 analysis	 were	 then	 used	 for	 the	 second	583	 round	of	 eQTL	mapping,	 allowing	us	 to	detect	 independent	 eQTL.	 If	 additional	584	 eQTL	 were	 identified	 from	 this	 second	 round	 of	 analysis,	 the	 process	 was	585	 repeated,	 correcting	 for	 the	 main	 effects	 of	 the	 top	 eSNP	 from	 the	 first	 and	586	 second	eQTL	using	multivariate	regression.	587	 	588	 For	 probes	 with	 a	 significant	 association	 with	 rs3820282,	 we	 performed	 a	589	 conditional	analysis	fitting	rs3820282	genotypes	as	a	fixed	covariate	and	testing	590	 for	secondary	effects	on	all	SNP	within	+/-	1MB	of	 rs3820282.	The	study-wide	591	 significance	of	secondary	eQTL	was	determined	as	0.05/	number	of	SNPs	tested.	592	 If	secondary	eQTL	were	identified,	we	continued	by	fitting	the	genotypes	of	the	593	 secondary	sentinel	eSNP	alongside	rs3820282.		594	 	595	
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We	 used	 two	 methods	 to	 distinguish	 between	 shared	 causal	 effects	 and	596	 coincidental	overlaps.	The	 first	 is	 the	Regulatory	Trait	Concordance	(RTC)	 test,	597	 which	 is	 a	 rank-based	 score	 test	 that	 accounts	 for	 differences	 in	 the	 local	 LD	598	 structure	between	estimated	eSNP	and	GWAS	effects	and	is	described	in	detail	in	599	 Nica	 et	 al.	 30.	 The	 second	 is	 a	 Summary-data-based	 Mendelian	 Randomization	600	 (SMR)	method,	 which	 tests	 the	 functional	 association	 between	 the	 expression	601	 level	 of	 a	 gene	 (measured	 by	 probes)	 and	 a	 trait	 through	 the	 regression	 of	602	 estimated	 effect	 sizes	 from	 the	 eQTL	 and	 GWAS	 analyses.	 Further	 details	 are	603	 provided	in	Zhu	et	al.31.	604	 	605	
Gene	expression	in	endometrial	tissue	606	
	607	
Sample	collection	608	 	609	 Endometrial	 tissue	 samples	 were	 collected	 by	 curettage	 from	 136	 women	610	 recruited	 through	 the	 Royal	 Women’s	 Hospital	 in	 Melbourne.	 Women	611	 undergoing	laparoscopic	surgery	provided	informed	written	consent	before	the	612	 operation.	Only	premenopausal	women	who	were	free	from	hormone	treatment	613	 (in	 the	 three	 months	 prior	 to	 surgery)	 were	 included	 in	 this	 study.	 Detailed	614	 patient	questionnaires,	past	and	present	clinical	histories,	pathology	findings	and	615	 surgical	 notes	 were	 recorded	 for	 each	 participant.	 A	 total	 of	 93	 women	 were	616	 surgically	diagnosed	with	endometriosis	by	visual	inspection	at	laparoscopy,	38	617	 women	 had	 no	 history	 of	 endometriosis	 and	 a	 negative	 result	 at	 laparoscopy,	618	 and	 five	 were	 unknown	 because	 the	 surgical	 examination	 was	 inconclusive.	619	 Endometrial	 cycle	 stage	 was	 determined	 following	 histological	 assessment	 at	620	 pathology	 (4	 Menstrual,	 4	 Early	 Proliferative,	 58	 Mid-Proliferative,	 12	 Late	621	 Proliferative,	 16	 Early	 Secretory,	 24	 Mid-Secretory,	 and	 18	 Late	 Secretory.	622	 Endometrial	 tissue	 samples	were	 taken	 from	 the	women	 by	 curette	 and	were	623	 stored	 in	RNAlater	 (QIAGEN)	 at	 -80°C	until	RNA	extraction.	Whole	blood	 from	624	 the	same	individuals	was	also	collected	to	investigate	the	effect	of	SNPs	located	625	 within	 1p36.12	 region	 on	 expression	 levels	 of	 cis-located	 transcripts	 in	626	 endometrial	 tissues.	 	 The	 study	 was	 approved	 by	 the	 Human	 Research	 Ethics	627	
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Committees	 of	 the	 Royal	 Women’s	 Hospital	 in	 Melbourne	 and	 the	 QIMR	628	 Berghofer	Medical	Research	Institute.	629	 	630	 DNA	was	extracted	from	the	whole	blood	and	DNA	samples	were	genotyped	for	a	631	 total	of	seven	variants	located	within	the	1p36.12	region	(five	top	GWA/imputed	632	 SNPs,	rs3820282,	rs56318008,	rs55938609,	rs12037376,	rs7521902,	top	eSNPs	633	 with	LINC00339,	rs12061255	and	a	4-bp	insertion/deletion	variant,	rs3036899)	634	 using	 the	 Sequenom	 MassARRAY	 technology	 (Sequenom	 Inc.,	 San	 Diego,	 CA,	635	 USA).	All	SNPs	had	call	rates	>95%.	636	 	637	 Total	RNA	was	extracted	from	homogenized	endometrial	tissues	using	RNA	lysis	638	 solution	(RLT	buffer)	and	RNeasy	Plus	Mini	Kit	according	to	the	manufacturer’s	639	 instructions	(QIAGEN,	Valencia,	CA).		RNA	quality	was	assessed	with	the	Agilent	640	 Bioanlayzer	 2100	 (Agilent	 Technologies,	 Santa	 Clara,	 CA),	 and	 concentrations	641	 were	determined	using	the	NanoDropND-6000.	250ng	of	RNA	was	amplified	and	642	 converted	 to	 biotinylated	 cRNA	 using	 the	 Ambion	 Illumina	 TotalPrep	 RNA	643	 Amplification	 Kit	 (Ambion).	 Expression	 profiles	 in	 endometrial	 tissue	 were	644	 generated	 by	 hybridising	 750	 ng	 of	 cRNA	 to	 Illumina	 HumanHT-12	 v4.0	645	 Beadchips	(as	described	above).		646	 	647	
Endometrial	tissue	gene	expression	normalisation	648	 Adjusted	 expression	 levels	 for	 each	 probe	 were	 transformed	 using	 a	 Quantile	649	 transformation69,70	to	achieve	a	stabilized	distribution	across	average	expression	650	 levels.	 Further	 normalisation	 was	 performed	 to	 allow	 expression	 levels	 to	 be	651	 compared	across	chips	and	genes.	This	was	achieved	fitting	a	linear	mixed	model	652	 as	described	above	where	!	is	an	unknown	vector	of	random	effects	of	the	batch	653	 (chip	and	chip	position)	in	endometrial	tissue	gene	expression	normalisation.	654	 	655	 Logistic	 regression	 was	 used	 to	 test	 for	 differential	 gene	 expression	 between	656	 cases	and	controls	and	between	phases	of	menstrual	cycle	of	the	tissue	samples	657	 (proliferative	 and	 secretory	 phases	 determined	 from	 histological	 evaluation),	658	 with	and	without	 adjusting	 for	phases	of	 the	menstrual	 cycle	 and	 case/control	659	 status,	respectively.	An	interaction	term	in	the	logistic	model	was	also	included	660	
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to	 assess	 for	 possible	 interaction	 between	 phases	 of	 the	 menstrual	 cycle	 and	661	 case/control	status.	662	 	663	
eQTL	analysis	664	 	665	 For	each	of	 the	seven	variants	examined,	a	cis-eQTL	analysis	was	conducted	 to	666	 investigate	the	putative	association	between	the	variant	and	expression	levels	of	667	 nearby	transcripts.	The	eQTL	analysis	was	performed	on	the	total	of	123	tissue	668	 samples	with	 recoded	 SNP	 genotypes	 based	 on	minor	 allele	 dosage	 and	 fitted	669	 linear	 regression	 models,	 with	 phases	 of	 the	 menstrual	 cycle	 included	 as	 a	670	 covariate	 in	 the	 model.	 Study-wide	 significance	 was	 determined	 using	 a	671	 Bonferroni	adjustment	(0.05/number	of	tests	performed).	672	 	673	
Cell	lines	674	 The	 Ishikawa	endometrial	 cancer	 cell	 line	 (kindly	provided	by	Pamela	Pollock,	675	 QUT,	Brisbane)	was	grown	in	DMEM	medium	with	10%	FCS	and	antibiotics.	The	676	 cell	 line	 was	 maintained	 under	 standard	 conditions,	 routinely	 tested	 for	677	
Mycoplasma	and	short	tandem	repeat	(STR)	profiled	to	confirm	cell	line	identity.		678	
	679	
Chromosome	conformation	capture	(3C)	680	 3C	libraries	were	generated	using	NcoI	as	described	previously72.	3C	interactions	681	 were	 quantitated	 by	 real-time	 PCR	 (qPCR)	 using	 primers	 designed	 within	682	 restriction	 fragments	(Supporting	material	 table	 3).	All	qPCR	was	performed	683	 on	 a	 RotorGene	 6000	 using	 MyTaq	 HS	 DNA	 polymerase	 (Bioline)	 with	 the	684	 addition	of	5	mM	of	Syto9,	annealing	temperature	of	66oC	and	extension	of	30s.	685	 3C	 analyses	 were	 performed	 in	 three	 independent	 3C	 libraries	 with	 each	686	 experiment	 quantified	 in	duplicate.	 BAC	 clones	 covering	 the	1p36	 region	were	687	 used	 to	 create	 artificial	 libraries	 of	 ligation	 products	 in	 order	 to	 normalize	 for	688	 PCR	 efficiency.	Data	were	 normalized	 to	 the	 signal	 from	 the	BAC	 clone	 library	689	 and,	 between	 cell	 lines,	 by	 reference	 to	 a	 region	 within	 GAPDH.	 All	 qPCR	690	 products	were	electrophoresed	on	2%	agarose	gels,	gel	purified	and	sequenced	691	 to	verify	the	3C	product.		692	 	693	
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Plasmid	construction	and	reporter	assays	694	 Promoter-driven	 luciferase	 reporter	 constructs	were	 generated	by	 insertion	 of	695	 DNA	fragments	(synthesized	by	GenScript)	containing	 the	LINC00339	or	CDC42	696	 promoters	 into	 the	 KpnI	 and	 NheI	 sites	 of	 pGL3-Basic.	 A	 1423	 bp	 fragment	697	 containing	 the	 Putative	 Regulatory	 Element	 (PRE1)	 or	 a	 2475	 bp	 fragment	698	 containing	the	PRE2	were	then	cloned	into	BamHI	and	SalI	sites	of	the	modified	699	 pGL3-promoter	constructs.	The	minor	(risk-increasing)	alleles	of	individual	SNPs	700	 were	 introduced	 into	 the	PRE	sequences	by	mutagenesis	 (GenScript).	 Ishikawa	701	 cells	were	 transfected	with	 equimolar	 amounts	of	 luciferase	 reporter	plasmids	702	 and	 50	 ng	 of	 pRL-SV40	 transfection	 control	 plasmid	with	 Lipofectamine	 2000.	703	 The	 total	 amount	 of	 transfected	 DNA	 was	 kept	 constant	 at	 600	 ng	 for	 each	704	 construct	by	the	addition	of	pUC19	as	a	carrier	plasmid.	Luciferase	activity	was	705	 measured	24	hr	post-transfection	by	 the	Dual-Glo	Luciferase	Assay	System.	To	706	 correct	 for	 any	 differences	 in	 transfection	 efficiency	 or	 cell	 lysate	 preparation,	707	
Firefly	luciferase	activity	was	normalized	to	Renilla	luciferase,	and	the	activity	of	708	 each	 construct	 was	measured	 relative	 to	 the	 promoter	 alone	 construct,	 which	709	 had	a	defined	activity	of	1.	Statistical	significance	was	tested	by	log	transforming	710	 the	 data	 and	 performing	 2-way	 ANOVA,	 followed	 by	 Dunnett’s	 multiple	711	 comparisons	test	in	GraphPad	Prism.		712	 	713	
Estrogen	induction	714	 Ishikawa	cells	were	 first	 incubated	with	10nM	Fulvestrant	(ICI	182780,	Sigma)	715	 for	48	hours,	then	transfected	using	Lipofectamine2000	and	treated	with	either	716	 100nM	17β-Estradiol	(Sigma)	or	DMSO	(vehicle	control)	for	24	hours.	Luciferase	717	 activity	was	measured	24	hr	post-transfection	as	described	above.	Quantitative	718	 PCR	(qPCR)	for	the	established	estrogen-regulated	gene	TFF1	was	performed	on	719	 Ishikawa	 total	 RNA	 extracted	 using	 Trizol	 (Life	 Technologies).	 qPCRs	 were	720	 performed	on	a	RotorGene	6000	(Corbett	Research)	with	a	TFF1	TaqMan	assay	721	 (Hs00907239_m1)	and	normalized	against	β-glucuronidase	(4326320E).	722	 	723	
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FIGURES	931	
	932	
Figure	 1	 |	 SNPs	 within	 the	 1p36.12	 region	 are	 associated	 with	 both	933	 endometriosis	 risk,	 and	 the	 expression	 levels	 of	 LINC00339	 and	 CDC42.	934	 Association	results	for	individual	SNPs	are	plotted	by	position	on	chromosome	1	935	 (X-axis)	 as	–log10	 p-values	 (Y-axis)	 for	 endometriosis	 risk	 (first	 panel),	936	
LINC00339	(second	panel)	and	CDC42	(third	panel)	expression	in	the	BSGS.	The	937	 relative	locations	of	genes	within	the	1p36.12	regions	are	shown	in	panel	4.	The	938	 fifth	panel	shows	the	relationship	between	rs3820282	genotypes	and	transcript	939	 expression	levels	in	BSGS	for	seven	genes	in	the	1p36.12	region.		940	 	 	941	
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	942	
	943	
	944	
Figure	 2	 |	Expression	 levels	of	LINC00339	 (left	hand	panels)	and	CDC42	 (right	945	 hand	 panels)	 with	 eQTL	 effects	 for	 the	 relationship	 between	 rs3820882	 and	946	 gene	 expression	 in	 blood	 (top	 panel);	 rs3820282	 and	 gene	 expression	 in	947	 endometrium	 (bottom	 panel).	 The	 overall	 estimated	 effect	 on	 LINC00339	948	 (ILMN_3272768)	of	each	additional	copy	of	rs3820282	endometriosis	risk	allele	949	 [A]	 is	 -0.86	 in	whole	blood	and	 -0.55	 in	endometrial	 tissue.	The	corresponding	950	 effect	in	CDC42	(ILMN_1675156)	is	0.24	and	0.13	respectively.		951	 	952	 	953	
	 	954	
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	955	
	956	
Figure	3	|	Candidate	causal	SNPs	are	located	within	PREs	that	interact	with	957	
the	LIN00339	or	CDC42	promoters.	(a)	The	location	of	candidate	causal	SNPs	958	 are	 represented	by	black	or	 red	 ticks,	 gene	structures	 are	depicted	with	exons	959	 (vertical	boxes)	 joined	by	 introns	 (lines).	3C	anchors	are	 shown	as	blue	boxes,	960	 frequently	 interacting	 NcoI	 fragments	 as	 grey	 boxes	 and	 Putative	 Regulatory	961	 Elements	 (PRE1,	 PRE2)	 as	 black	 boxes.	 (b)	 3C	 interaction	 profiles	 between	962	
LINC00339,	CDC42	or	WNT4	promoters	and	the	1p36	risk	region	in	Ishikawa	cell	963	 lines.	3C	anchors	are	shown	as	blue	boxes	and	frequent	interactions	highlighted	964	 with	 red	 connecting	 bars.	 Graphs	 represent	 one	 of	 three	 biological	 replicates.	965	 Error	bars	 represent	SD.	(c)	Luciferase	 reporter	assays	 in	 Ishikawa	cells.	PREs	966	 containing	 the	major	SNP	alleles	 (Ref)	were	cloned	downstream	of	 target	gene	967	 promoter-driven	 constructs.	 Minor	 (risk-increasing)	 SNP	 alleles	 were	968	 engineered	 into	 the	 constructs	 and	 are	 designated	 by	 the	 rs	 ID	 of	 the	969	 corresponding	 SNP.	 Error	 bars	 denote	 95%	 confidence	 intervals	 from	 three	970	 independent	experiments.	P-values	were	determined	by	2-way	ANOVA	followed	971	 by	 Dunnett’s	 multiple	 comparisons	 test	 (*P<0.05,	 **P<0.01).	972	
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Table 1 | Endometriosis association information for common SNPs with the key SNP (rs3820282) and significant association with endometriosis 
risk (P<5×10-3). Fine mapping results were from 7,090	individuals	(2,594	cases	and	4,496	controls)	in	the	combined	Australian	dataset.	  
	
 
# Risk allele frequency 
* Odd ratios were calculated for the risk allele 		 	
SNPs Position(hg19) LD with  
rs3820282 
(r2) 
RA OA RAF#case RAF#control OR* P 
rs3820282 22468215 1 A G 0.189 0.162 1.244(1.126-1.375) 1.84×10-5 
rs56318008 22470407 0.95 T C 0.186 0.159 1.243(1.125-1.374) 2.06×10-5 
rs55938609  22470451 0.95 C G 0.186 0.159 1.240(1.121-1.372) 2.88×10-5 
rs12037376 22462111  0.90 A G 0.193 0.167 1.229(1.113-1.356) 4.24×10-5 
rs2235529 22450487 0.84 A G 0.188 0.161 1.216(1.107-1.335) 4.61×10-5 
rs12404660 22458794 0.79 G A 0.222 0.195 1.216(1.107-1.336) 4.71×10-5 
rs7412010 22436446 0.90 C G 0.196 0.170 1.211(1.100-1.333) 9.71×10-5 
rs7515106 22473410 0.61 C T 0.240 0.213 1.174(1.077-1.280) 2.66×10-4 
rs2473295 22354866 0.05 G A 0.771 0.748 1.156(1.058-1.263) 1.39×10-3 
rs760923 22357217 0.05 T G 0.770 0.748 1.154(1.057-1.261) 1.44×10-3 
rs7521902 22490724 0.61 A C 0.264 0.240 1.138(1.048-1.236) 
 
2.08×10-3 
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Table	2	|	Effect	of	the	fine-mapped	(rs3820282)	and	original	GWA	sentinel	(rs7521902)	endometriosis	SNPs	on	the	expression	levels	of	transcripts	located	within	1p36.12	locus.	Expression	levels	of	probes	were	measured	in	whole	blood	for	862	individuals	from	the	Brisbane	Systems	Genetics	Study23.		
	
	 	 	 -Log10(p-value)	 Effect	(SE)	
Gene	 Probe	 Probe	start	(bp)	 rs3820282	[A]	 rs7521902	[A]	 rs3820282	[A]	 rs7521902	[A]	
USP48	 ILMN_2285141	 22005116	 7.1x10-2	 6.1x10-1	 -0.07	(0.07)	 -0.03	(0.06)	
USP48	 ILMN_1756873	 22005253	 3.8x10-1	 7.4x10-1	 -0.06	(0.07)	 -0.02(0.06)	
USP48	 ILMN_1738572	 22054538	 7.4x10-1	 8.7x10-1	 0.02	(0.07)	 0.01	(0.06)	
USP48	 ILMN_1777726	 22055186	 7.4x10-1	 8.1x10-2	 -0.03	(0.10)	 0.16	(0.09)	
LDLRAD2	 ILMN_1734125	 22151317	 4.7x10-1	 1.5x10-1	 -0.14	(0.19)	 0.22	(0.15)	
LINC00339	 ILMN_3194087	 22357217	 1.9x10-54	 1.2x10-18	 -1.00	(0.06)	 -0.49	(0.05)	
LINC00339	 ILMN_3272768	 22357427	 1.0x10-34	 2.5x10-14	 -0.86	(0.07)	 -0.45	(0.06)	
CDC42	 ILMN_1675156	 22379185	 4.5x10-4	 4.9x10-2	 0.24	(0.07)	 0.11	(0.06)	
CDC42	 ILMN_1738424	 22419001	 1.3x10-1	 3.7x10-1	 0.10	(0.07)	 0.05	(0.06)	
ZBTB40	 ILMN_1784037	 22854693	 2.4x10-2	 1.2x10-1	 -0.15	(0.07)	 -0.09	(0.06)	
EPHA8	 ILMN_1756989	 22929712	 4.3x10-1	 6.6x10-1	 -0.06	(0.07)	 0.03	(0.06)	
C1QA	 ILMN_1737918	 22965739	 7.1x10-1	 5.2x10-1	 0.05	(0.12)	 -0.07	(0.10)	
C1QC		 ILMN_1785902	 22974217	 6.1x10-1	 6.3x10-1	 -0.09	(0.17)	 -0.07	(0.14)	
C1QB		 ILMN_1796409	 22987790	 6.1x10-1	 9.7x10-1	 0.08	(0.16)	 -0.01	(0.13)	
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Table	3	|	SNP	effects	for	transcription	levels	measured	in	endometrial	tissue.		
	
	 	 	 	 	 	 WNT4	
(ILMN_1666392)	
	 CDC42	
(ILMN_1675156)	
	 LINC00339	
(ILMN_1901198)	
	
SNP	 Position	
(hg19)	
LD*		
(r2)	
Endo	
-log10(P)	
RA	 OA	 Effect	of	
RA	
-log10(P)	 Dist	from	
SNP(bp)	
Effect	of	
RA	
-log10(P)	 Dist	from	
SNP(bp)	
Effect	of	
RA	
-log10(P)	 Dist	
from	
SNP(bp)	
rs3820282	 22468215	 1	 1.8x10-5	 A	 G	 0.08	 5.6x10-1	 21735	 0.07	 5.4x10-1	 89030	 -0.52	 2.3x10-8	 110828	
rs56318008	 22470407	 0.95	 2.1x10-5	 T	 C	 0.15	 3.1x10-1	 23926	 0.03	 7.7x10-1	 91221	 -0.47	 1.5x10-6	 113019	
rs55938609		 22470451	 0.95	 2.9x10-5	 C	 G	 0.14	 3.3x10-1	 23971	 0.03	 7.5x10-1	 91266	 -0.47	 1.8x10-6	 113064	
rs12037376	 22462111	 0.90	 4.3x10-5	 A	 G	 0.09	 5.2x10-1	 15630	 0.07	 5.3x10-1	 82925	 -0.53	 2.2x10-8	 104723	
rs7521902	 22490724	 0.61	 2.1x10-3	 A	 C	 0.20	 9.7x10-2	 44243	 0.004	 9.5x10-1	 111538	 -0.35	 4.4x10-5	 133336	
rs12061255	 22350297	 0.07	 7.1x10-1	 T	 C	 0.05	 6.4x10-1	 -96315	 0.05	 5.9x10-1	 -29020	 0.47	 1.4x10-9	 -7222	
rs3036899	 22357435	 0.05	 -	 TCTT	 -	 0.07	 4.8x10-1	 -89045	 0.009	 9.1x10-1	 -21750	 0.21	 4.2x10-3	 48	
	
*	LD	(r2)	with	the	sentinel	rs3820282	for	association	with	endometriosis	risk			
